Adults

Dosage varies significantly based on the indication and patient's medical condition. For Multiple Myeloma, typically 25 mg orally once daily for 21 days of a 28-day cycle, in combination with dexamethasone. For MDS 5q deletion, typically 10 mg orally once daily. Always consult physician.

Elderly

Dosage adjustments may be necessary based on renal function and tolerability, similar to younger adults.

Renal_impairment

Significant dosage reduction required based on creatinine clearance (e.g., CrCl 30-60 mL/min: 10 mg daily or every other day; CrCl <30 mL/min: 5 mg daily or every other day).

Onset

Not directly applicable as it's a chronic treatment, but immunomodulatory effects can start within days to weeks.

Excretion

Primarily excreted renally, with approximately 66% found in urine as unchanged drug.

Half life

Approximately 3-5 hours.

Absorption

Rapidly absorbed after oral administration, peak plasma concentrations typically reached within 0.5-6 hours.

Metabolism

Minimally metabolized; primarily excreted unchanged.

Digoxin

Lenalidomide may increase Digoxin levels, monitor closely.

Dexamethasone

Enhances efficacy in multiple myeloma, but also increases risk of thromboembolism.

Erythropoietic stimulating agents (ESAs)

Increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE).